BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 21803707)

  • 21. Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer.
    Rothschild SI; Gautschi O; Lara PN; Mack PC; Gandara DR
    Curr Opin Oncol; 2011 Mar; 23(2):150-7. PubMed ID: 21119513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The tissue is the issue: personalized medicine for non-small cell lung cancer.
    Hirsch FR; Wynes MW; Gandara DR; Bunn PA
    Clin Cancer Res; 2010 Oct; 16(20):4909-11. PubMed ID: 20926402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrating new targeted agents into the treatment of non-small-cell lung cancer.
    Thatcher N
    Lung Cancer; 2006 Dec; 54 Suppl 2():S25-31. PubMed ID: 17056150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beyond EGFR TKI in EGFR-mutant non-small cell lung cancer patients: main challenges still to be overcome.
    Remon J; Morán T; Reguart N; Majem M; Carcereny E; Lianes P
    Cancer Treat Rev; 2014 Jul; 40(6):723-9. PubMed ID: 24759598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modern treatment of lung cancer: case 1. Amplification and mutation of the epidermal growth factor receptor in metastatic lung cancer with remission from gefitinib.
    Schwab R; Pinter F; Moldavy J; Papay J; Strausz J; Kopper L; Keri G; Pap A; Petak I; Oreskovich K; Mangel L
    J Clin Oncol; 2005 Oct; 23(30):7736-8. PubMed ID: 16234532
    [No Abstract]   [Full Text] [Related]  

  • 26. Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years.
    Cufer T; Ovcaricek T; O'Brien ME
    Eur J Cancer; 2013 Apr; 49(6):1216-25. PubMed ID: 23265700
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidermal growth factor receptor mutations in lung cancer.
    Sharma SV; Bell DW; Settleman J; Haber DA
    Nat Rev Cancer; 2007 Mar; 7(3):169-81. PubMed ID: 17318210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Directed therapies in lung cancer: new hope?
    Parente Lamelas I; Abal Arca J; Fírvida Pérez JL
    Arch Bronconeumol; 2012 Oct; 48(10):367-71. PubMed ID: 22551924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Potential Epigenetic Therapy for NSCLC.
    Cancer Discov; 2015 Apr; 5(4):341. PubMed ID: 25724377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [I. What is the Standard Treatment of EGFR-TKIs? Did EGFR-TKIs Improve Treatment for Non-Small Cell Lung Cancer?].
    Urata Y; Satouchi M
    Gan To Kagaku Ryoho; 2015 Aug; 42(8):931-4. PubMed ID: 26353389
    [No Abstract]   [Full Text] [Related]  

  • 31. [Molecular targeted therapies and cytotoxics: Friends or foes?].
    Vignot S; Zalcman G
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S91-2. PubMed ID: 26118883
    [No Abstract]   [Full Text] [Related]  

  • 32. Exploring the future of non-small cell lung cancer treatment.
    Ramalingam S
    Manag Care; 2005 Feb; 14(2 Suppl):9-13; discussion 13-4. PubMed ID: 15776956
    [No Abstract]   [Full Text] [Related]  

  • 33. Gefitinib: phoenix from the flames.
    Lancet Oncol; 2009 Aug; 10(8):737. PubMed ID: 19647191
    [No Abstract]   [Full Text] [Related]  

  • 34. A tabulated summary of targeted and biologic therapies for non-small-cell lung cancer.
    Somaiah N; Simon NG; Simon GR
    J Thorac Oncol; 2012 Dec; 7(16 Suppl 5):S342-68. PubMed ID: 23160320
    [No Abstract]   [Full Text] [Related]  

  • 35. Epidermal growth factor receptor: pathway, therapies, and pipeline.
    Goffin JR; Zbuk K
    Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Personalized treatment in non-small cell lung cancer].
    Campos-Parra AD; Cruz-Rico G; Arrieta O
    Rev Invest Clin; 2012; 64(4):377-86. PubMed ID: 23227588
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacogenomics of lung cancer: with a view to address EGFR-targeted therapies.
    Joshi VA; Kucherlapati R
    Pharmacogenomics; 2007 Sep; 8(9):1211-20. PubMed ID: 17924836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MicroRNA-200a Targets EGFR and c-Met to Inhibit Migration, Invasion, and Gefitinib Resistance in Non-Small Cell Lung Cancer.
    Zhen Q; Liu J; Gao L; Liu J; Wang R; Chu W; Zhang Y; Tan G; Zhao X; Lv B
    Cytogenet Genome Res; 2015; 146(1):1-8. PubMed ID: 26184032
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phosphatidykinosital 3-kinase and mammalian target of rapamycin pathway in non-small-cell lung cancer.
    Massarelli E; Papadimitrakopoulou VA
    J Thorac Oncol; 2012 Dec; 7(16 Suppl 5):S379-82. PubMed ID: 23160325
    [No Abstract]   [Full Text] [Related]  

  • 40. Knockdown of the epidermal growth factor receptor gene to investigate its therapeutic potential for the treatment of non-small-cell lung cancers.
    Shien K; Ueno T; Tsukuda K; Soh J; Suda K; Kubo T; Furukawa M; Muraoka T; Maki Y; Tanaka N; Yamamoto H; Kiura K; Mitsudomi T; Toyooka S; Miyoshi S
    Clin Lung Cancer; 2012 Nov; 13(6):488-93. PubMed ID: 22503506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.